common despite having received pre-medication with ondansetron, a standard preventive
treatment. This study aims to reduce the incidence of significant nausea and/or vomiting
with the addition of the NK1-antagonist aprepitant to standard ondansetron treatment. This
study will also assess the safety and tolerability of prolonged administration of aprepitant
over the 4 to 6 week period of radiation treatment.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
- Cancer Help Line: (800) 639-6918
- Email: firstname.lastname@example.org
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.